397 F.2d 656 | D.C. Cir. | 1968
Lead Opinion
The Commissioner of Patents appeals from an order of the District Court directing him to issue a patent to Appellee on two claims of a patent application.
Admitting that the Patent Office is taking a new and “revoluntionary approach,”
The factual background can be stated briefly. Appellee’s application consisted of six claims including generic, specific, and process claims. The Examiner rejected five of the claims in light of four prior art references, and the last claim was cancelled. The Examiner also found that a “rule 132” affidavit,
Apparently finding structural obviousness, the District Court determined that the existence of novel beneficial properties in the claimed compounds served to overcome the finding of obviousness due to structural similarities. In order to meet the prior art references, Appellee introduced evidence showing novel vermicidal properties of the claimed compounds not disclosed or suggested in the prior art. Evidence was also introduced showing the enhanced effectiveness of the compounds as intermediates in the preparation of patented sedatives and antihistamines.
(1)
Structural Obviousness
The third statutory criteria for the grant of a patent, “nonobvious
if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains.
In the Graham case the Supreme Court, for the first time, devoted itself to an extensive discussion of the concept of “non-obviousness” as codified in section 103. Some further clarification seems in order in what appears to be a blurred area of patent law.
The Commissioner asserts that under the standard of non-obviousness, structural obviousness of the claimed compound from the prior art reference is an absolute bar to a patent. While conceding that the language of section 103, “subject matter as a whole,” refers not only to the chemical structure or formula, but can include properties of the structure or compound and the results it can accomplish, the Commissioner constructs the following argument:
[I] t should be quite clear that the antecedent of “subject matter as a whole” in Section 103 of 35 U.S.C. is “subject matter sought to be patented”, which expression means obviously the claimed, subject matter, as distinguished from subject matter which is merely disclosed in applicant’s specifications but not included in the claims.
Commissioner’s Reply Brief, p. 2 (emphasis in original). But cf. General Tire & Rubber Co. v. Brenner, 127 U.S.App.D.C. 102, 381 F.2d 270 (1967).
Initially we have some doubt as to the question of structural obviousness. The Examiner found that the concept of the claimed compound was either clearly taught or obvious
The issue raised by the Commissioner is the extent to which this structural obviousness operates in the determination of the non-obviousness of the subject matter as a whole under section 103. Structural obviousness generally arises because the claimed compound is — in the chemists’ jargon — a homolog, analog, or isomer of the prior art references.
Perhaps the best expression of the view that obvious but novel compounds should be considered in conjunction with their properties is Judge Rich’s excellent opinion in Application of Papesch, 315 F.2d 381, 50 CCPA 1084 (1963). After discussing the various authorities and concluding that the statute required a determination of obviousness and patent-ability after consideration both of the chemical structure and the pharmaceuti
From the standpoint of patent law, a compound and all its properties are inseparable; they are one and the same thing. The graphic formulae, the chemical nomenclature, the systems of classification and study such as the concepts of homology, isomerism, etc., are mere symbols by which compounds can be identified, classified, and compared. But a formula is not a compound and while it may serve in a claim to identify what is being patented, as the metes and bounds of a deed identify a plot of land, the thing that is patented is not the formula but the compound identified by it. And the patentability of the thing does not depend on the similarity of its formula to that of another compound but of the similarity of the former compound to the latter. There is no basis in law for ignoring any property in making such a comparison. An assumed similarity based on a comparison of formulae must give way to evidence that the assumption is erroneous.
Id. at 391. The sound reasoning of the Papesch case has been unanimously and repeatedly reaffirmed by the Court of Customs and Patent Appeals.
First, it would appear that the Commissioner’s position is hardly supported, but on the contrary is substantially undermined, by Graham v. John Deere Co., 383 U.S. 1, 86 S.Ct. 684 (1966), although he seems to place great reliance on this case. Graham was the first authoritative opinion dealing with the question of obviousness under section 103. It is clear from that unanimous decision that hard and fast rules of general applicability are impossible to achieve under section 103. Rather, the section “lends itself to several basic factual inquiries,” enumerated by the Supreme Court:
Under § 103, the scope and content of the prior art are to be determined; differences between the prior art and the claims at issue are to be ascertained; and the level of ordinary skill in the pertinent art resolved. Against this background, the obviousness or nonobviousness of the subject matter is determined.
Id. at 17, 86 S.Ct. at 694. It seems rather elementary to us that the “background” referred to for determination of obviousness clearly is not limited to the issue of structural similarity. Position isomerism, as involved here, focuses on close structural similarity which is to be taken into consideration with all other relevant facts in measuring the standard of obviousness under section 103. E. g., Application of Wiechert, 370 F.2d 927, 933, 54 CCPA 957 (1967); Application of Mehta, 347 F.2d 859, 52 CCPA 1615 (1965). This, we think, is the teaching of Graham.
While agreeing with this basic factual approach of Graham, the Commissioner asserts that where structural obviousness is assumed, “inquiry by the court into the issue as to whether the claimed subject matter has unexpected beneficial properties is prohibited under the Graham case.” He then argues that this prohibition is derived from the fact that the issue of chemical properties is, at best, a “secondary consideration” under Graham. It is true that the Court in Graham mentions certain secondary eon
A second factor, to which we have already alluded, is the rare occurrence in finding a completely new compound whose molecular arrangements cannot be predicted, at least on paper. If we are to accept a determination of structural obviousness which cannot be rebutted by evidence of chemical, pharmaceutical, or biological properties, few pharmaceutical compounds will be patented, and the incentive aspect of the patent system, which is basic, will be lost from an important area.
A third salient point comes from the Commissioner himself. The Patent Office Rules, particularly Rule 132, permit an applicant to meet an initial rejection with proof of unob.viousness. A traditional method has always been to permit evidence of novel properties or utility. Indeed, prior to the Graham case, this was the Commissioner’s consistent position. E. g., Brief for Commissioner, Application of Higgins, 369 F.2d 414 (C.C. P.A.1966). We find nothing in Graham which calls for the radical shift in the law proposed.
Fourth, the patent statutes as a whole would seem to favor the Papeseh standard. The section 101 criteria — utility — is largely dependent on the question of what the compound will do, and its properties are of prime consideration here. See Brenner v. Manson, 383 U.S. 519, 86 S.Ct. 1033, 16 L.Ed.2d 69 (1966).
The Commissioner, in addition to reliance on Graham, refers to a recent decision of this court to support his position, Hays v. Brenner, 123 U.S.App.D.C. 96, 357 F.2d 287 (1966). He views Hays as holding that section 103 is an absolute bar to a patent where obviousness is assumed. It is true that some of the language in Hays affords a colorable basis for his contention, but it is also clear that the holding was not directed to the question of structural obviousness alone but to obviousness of the subject matter as a whole, a completely different situation. In Hays we made no effort to determine what the claimed subject matter was in the case of a chemical compound. The plain language of section 103 makes it clear that obviousness of the subject matter as a whole is not limited to a consideration of structure; and this is con
In rejecting the broad proposition advanced by the Commissioner we should make it clear that structural obviousness is certainly a large factor to be considered in the determination of obviousness of the subject matter as a whole. Whether it is called an inference of obviousness, Application of Mills, 281 F.2d 218, 223 (C.C.P.A. 1960), a prima facie showing of obviousness, Application of Rosselet, 347 F.2d 847, 850, 52 CCPA 1533 (1965), or a presumption of obviousness, Application of Henze, 181 F.2d 196, 201, 37 CCPA 1009 (1950), is, we believe, immaterial.
The final assertion from the Commissioner’s sweeping contentions is interesting but does not compel a contrary result. He views the claim as defining by name and diagram a mental concept of a chemical compound which, to the ordinary chemist, would convey both the structure and characteristics of a family of compounds. The Commissioner would have us adopt the following logic: Since section 103 refers to “subject matter as a whole,” the antecedent of which is “subject matter sought to be patented,” these obviously refer only to the claimed compound; hence, if that claim does not specifically refer to the particular property which demonstrates non-obviousness, it does not distinctly claim the invention as required in section 112, paragraph 2, but instead claims that compound for all uses and properties, thus overclaiming and foreclosing the public from using the compound in an unrelated, but unobvious, field.
Advance in the Art
The Commissioner’s second claim of error concerns some language in the District Court’s opinion to the effect that “advance in the art” is not a condition for patentability.
From the introductory sentence in Graham it is clear that the Supreme Court was well aware of the distinction between statutory conditions of patent-ability and constitutional standards
Innovation, advancement, and things which add to the sum of useful knowledge are inherent requisites in a patent system which by constitutional command must “promote the Progress 0f * * * usefui Arts.” This is the standard expressed in the Constitution and it may not be ignored.
383 U.S. at 6, 86 S.Ct. at 688 (emphasis added in part). Appellee and the District Court are correct in stating that advancement is not one of the three conditions of patentability under the statutes. But this overlooks the clear, and at least implied, discussion in Graham of the constitutional standard. The conditions effectuating this standard are for congressional determination, but the standard itself is to be implemented by the Commissioner and the courts.
The requirement of advancement is an illusory one, focusing on something incapable of precise definition. Other than an implication that advancement was the equivalent of “Progress” as used in the constitutional phrase,
The Commissioner has conceded in this reply and elsewhere that a determination of unobviousness in most cases, but not necessarily all, is equivalent to an advance in the art. Appellee asserts that the congressional creation of the third statutory condition, non-obviousness, accomplished the constitutional purpose of the patent provision, and incorporates the concept of advance in the art. Indeed, Graham draws a close parallel between the determination of non-obviousness and advancement to the extent that the inquiry into non-obviousness “comports with the constitutional structures,” 383 U.S. at 17, 86 S.Ct. 684. Similarly, it is quite clear that the pivotal condition discussed in Graham, non-obviousness, which was added to the patent statute in 1952, strongly equates itself with the judicial condition of “invention,” previously so long used. Both formulations, invention and non-obviousness, “place emphasis on the pertinent art existing at the time the invention was made and both are implicitly tied to advances in that art,” id. at 14, 86 S.Ct. at 692 (emphasis added).
But, while the major emphasis may be placed on the condition of non-obviousness, we do not find that such a determination, ipso facto, is also an ultimate determination on the question of advancement. The other two statutory requisites, novelty and' utility, have always been thought to be separate and independent conditions. If advance in the useful art is the necessary standard to sustain patentability, the more logical view is that the three independent statutory conditions are not separate from advancement but are the very indicia of it, in particular the condition of non-obviousness. See Note, 54 Geo.L.J. 1320, 1339 (1966).
Under this analysis we have some difficulty in perceiving how a claimed compound which is new, useful, and unobvious can still not constitute an advance in the art.
If, as is asserted by amicus, the Commissioner is really contending that before any claimed subject matter is patentable, it must “advance the art” in the sense that it is demonstrated to be better than that which preceded it in terms of cost, performance, or otherwise, we must reject such a view.
Progress is most effectively promoted by protecting those who enrich the art as well as those who improve it. Even though their inventions are not as good as what really exists, such inventors are not being rewarded for standing still or for retrogressing, but for having invented something. The system is not concerned with the individual inventor’s progress but only with what is happening to technology.
Rich, Principles of Patentability, 28 Geo.Wash.L.Rev. 390, 402 (1960).
This is our understanding of the standard of advancement as interpreted in Graham. It is correct that Graham admonished the Commissioner to “tighten up” on applications, and mildly rebuked him for leniency in applying the conditions of section 103. 383 U.S. at 18, 86 S.Ct. 684. But this was not the creation of a new requirement of patentability
Our analysis of the District Judge’s opinion shows that the statement that advance in the art was not a condition of patentablity meant no more than that the constitutional standard of advancement was demonstrated by the utility of the claimed compound over the prior art through its unobvious anthelmintic properties, regardless of the relative superiority in this respect. This seems to be the essence of the entire paragraph which the Commissioner attacks as erroneous. Surely we could impute no other interpretation to the opinion and we are satisfied that the District Judge did not mean that advance in knowledge was unnecessary to patentability.
(3)
Sufficiency of Evidence
In an effort to overcome the burden of structural similarity with the prior art, Appellee specified in its complaint in the District Court, as it had done in its application before the Patent Office, that the claimed compound had unexpected utility in two areas. First, evidence was offered showing that the claimed compound was superior to three of its prior art isomers as a vermicide, a utility alleged to be unobvious in the prior references. Second, evidence was offered showing that patented antihistimines and sedatives had greater supeority when prepared from derivatives containing the claimed compound than when prepared under the then-known
(a) Direct Utility as a Vermicide
The first phase of Appellee’s evidence consisted of comparative tests between the claimed compound and three prior art isomers, demonstrating the superiority of the claimed compound when utilized as a vermicide. These tests, found by the District Court to be universally recognized showed the following: (1) the
claimed compound was equal in anthelmintic activity on ascaris worms
This comparative evidence was fully adopted by the District Court and led to that Court’s conclusion that the claimed compound would be “equal or superior as a vermicide” when compared with the prior art isomers. 251 F.Supp. at 628. Furthermore, the District Court found that none of the prior art references relied upon suggested that the azaphenothiazines (the claimed compound and its prior art isomers) would be useful as a vermicide. Thus, the District Court concluded :
When the prior art does not contain the slightest suggestion that the properties of a claimed compound would make it useful for a certain advantageous purpose, then the utility itself is unobvious, and it is unnecessary for an applicant to prove by comparative tests that his compound is more useful for the certain purpose than closely related prior art compounds.
Ibid.
The Commissioner makes two arguments directed at this evidence. First, he argues that the comparative tests did not afford a sufficient basis for the District Court’s unequivocal holding that the claimed compound was equal or superior to the prior art isomers when utilized as a vermicide.
As we have previously noted, see note 12 swpra, we are governed in our review of the factual findings of the District Court by the “clearly erroneous” standard of Rule 52 of the Federal Rules of Civil Procedure. On the basis of the evidence produced on comparative tests, we cannot say that the District Court erred in holding that the claimed compound “was equal or superior as a vermicide to the other three isomers * * 251 F.Supp. at 628. Thus we reject the Commissioner’s first argument.
The Commissioner’s second argument is directed at the statement of the District Judge just quoted, to the effect that an applicant need not prove that his claimed compound is more useful by comparative testing where the prior art does not suggest that the properties of the claimed compound would be useful for a certain purpose.
In support of its legal conclusion, the District Court relied upon E. I. DuPont
In the total absence of evidence in the record to indicate that the amber glass disclosed by Lyle [the prior art reference] would be expected to have desirable electrical insulating properties, we can find no justification for placing the burden on applicant to conduct experiments to determine the insulating properties of the colored glass disclosed by Lyle.
Id. at 874.
In addition to distinguishing these cases, the Commissioner’s principal argument is that where an applicant is attempting to demonstrate that his claimed compound possesses novel or unobvious beneficial properties he must show that such properties are not in fact possessed by the prior art reference. Under the ruling of the District Judge no such showing was required of Appellee. The Commissioner relies upon Application of Henze, 181 F.2d 196, 37 CCPA 1009 (1950).
In Henze, the application was for claimed compounds one of which was the next higher homolog of a compound disclosed in a prior publication.
The examiner had held, * * * that the claims in issue were unpatentable, lacking invention over the disclosure of the publication, because the appellant had failed to show that the compounds claimed had an unexpected beneficial property not possessed by the lower adjacent homologue disclosed in the publication. The examiner held that the affidavit did not aid in conferring patentability upon the rejected claims because there was no showing that the lower homologue would not yield results similar to the claimed compounds under certain dosages. *■»***«
The burden is on the applicant to rebut that presumption [of unpatentability] by a showing that the claimed compound possesses unobvious or unexpected beneficial properties not actually possessed by the prior art homologue. It is immaterial that the prior art homologue may not be recognized or known to be useful for the same purpose or to possess the same properties as the claimed compound.
Id. at 200-201 (emphasis in the original). The rationale articulated for the rule was that the characteristics normally possessed by members of a homologous series are generally the same, varying gradually from one member to the next. Thus, a chemist knowing the properties of one member of the series would have little difficulty predicting the properties of the adjacent members of the homologous series. Ibid.
The Henze case and its progeny have brought little clarification to the field of patent law. See note 20, supra. The case itself applied its doctrine to the question of adjacent homologs. Isomerism, as involved in the present case, is somewhat different; it is basically a structural classification not dependent upon similarities of properties as is homology. See Morrison & Boyd, Organic Chemistry 32 (2d ed. 1966); Collins, supra note 20,
In one line of cases, that court has made it quite clear that Henze should be limited to its factual situation, even to the extent of excluding the question of non-adjacent homologs from its application.
Although not cited by the parties, we think Application of Riden, 318 F.2d 761, 50 CCPA 1411 (1963), has some bearing on the issue. In Riden the application was for certain compounds useful as pesticides. The primary reference disclosed no use, either as an insecticide or for any other purpose, id. at 762. Other references, however, did disclose utility as fungicides. The court found
There is no showing in this case that the compounds of claims 3 and 8 differ by more than a matter of degree from the compounds of Boehme et al. [the prior reference] in any properties. It is true that Boehme et al. does not teach that the compounds have insecticidal properties, but there is no showing that they do not. Had there been evidence of a new property of the closely related compounds not possessed by the analog, a different case might arise. * * * Such evidence was not forthcoming during the prosecution of the ease. Indeed, the specification of appellants’ application indicates that the Boehme et al. compounds have the same properties but differ only in degree, * * *.
Id. at 764 (emphasis in the original). Thus, Riden would seem to indicate that even when the prior art was not alleged to possess the same properties, it is incumbent upon the applicant to make a comparison to see if it possessed the same
We recognize, of course, that the best method of demonstrating patentability under Papesch and its progeny by the existence of a novel and unobvious property is through the use of comprehensive comparative testing. Nevertheless, on the whole record we are satisfied that the District Judge’s conclusion of law concerning comparative testing was correct as applied to the facts of this case. We reach this conclusion on the basis of the limited comparative testing here, which, although it did not disprove the existence of the same properties in the prior art, strongly suggests, by reason of the vastly superior results obtained, that those new results derived from the existence of a novel property in the claimed compound; by limiting Henze to its facts, as the Court of Customs and Patent Appeals has done; and by what we read as to the meaning of the additional evidence adduced in this case. It should be recalled that Appellee attempted to overcome the burden of structural obviousness through two evidentiary showings. In the first place, as we have indicated, evidence was offered to show new and unexpected properties and novel utilization of the claimed compounds. Had that been the only evidence offered we, and the District Judge as well, might have required further comparative testing. But Appellee went on to offer further evidence of a secondary nature — the indirect utility of the claimed compound as an intermediate for the production of known drugs with greater effectiveness than when prepared under then-existing methodology. In light of this dual approach we find that the District Judge’s conclusion of law not requiring comparative tests to be correct.
(b) Indirect Utility as an Intermediate
The second phase of Appellee’s evidence consisted of comparative tests between the claimed compound and its three prior art isomers with respect to their value as an intermediate in the preparation of two end products, a patented sedative and a patented antihistamine. This evidence disclosed that when the patented compounds were prepared from the claimed compounds they had a greater sedative and antihistaminic effect and greater therapeutic ratio than when the patented compounds were prepared from the three prior art isomers. Appellee claims that these tests demonstrate some novel and unique property in the claimed compound and that one skilled in the art would ascribe to the claimed compounds the contributing cause for the differences in end-product results.
The Commissioner’s argument is tied in with his earlier evidentary contentions just discussed. There he claimed that the direct evidence comparing the prior art with the claimed compound did not sufficiently disclose a novel property in the prior art. Since that evidence was insufficient, the Commissioner continues, the only basis for granting the patent was the District Judge’s reliance on the evidence in question in this aspect of the appeal. The error here, the Commissioner claims, is a violation of the “best evidence” rule. Relying on a series of eases, the Commissioner argues that the District Court opinion violated the well-known rule that evidence of new properties or unexpected results possessed by final products made directly from intermediates or derivatives (i. e., the claimed compounds) is inadmissible to prove patentability because of the remoteness of the relation back to the intermediate.
The Solicitor in his brief relies upon the rule which had its genesis in Application of Finley, 174 F.2d 130, 36 CCPA 998 (1949). In Finley the claimed compound was an ester which, when converted to its calcium salt, produced an
We agree with the Solicitor that the best evidence rule has a sound basis for application in the patent field. But, the rule is not “hard and fast,” Application of Widmer, supra, note 41, 353 F.2d at 759. Secondary evidence runs a greater risk of failing the relevancy test of admissibility in proportion to its remoteness from the claimed subject matter, but the question of remoteness is a question of law to be determined on the basis of the subject matter as a whole.
We hold the District Court was correct in its application of the rule. Several reasons compel this conclusion. In all of the cases relied upon by the Solicitor, the secondary evidence was the only evidence presented, or the secondary use was the only use specified. Here, however, both direct evidence and secondary evidence was presented. In such a situation we think that the trier of facts is permitted to consider the secondary evidence as admissible evidence. Since this case was decided, the Court of Customs and Patent Appeals has expressly relied upon the opinion now under review for the proposition that the secondary evidence -is admissible. Application of Diamond, supra note 41, 360 F.2d at 219-220. Certainly, if the District Judge’s application of the best evidence rule had been in conflict with the views of the Court of Customs and Patent Appeals, they would hardly have cited his decision in this case. Having amply predicated admissibility on the basis of these two facts, we cannot say that the District Judge was clearly erroneous in finding that the secondary evidence also demonstrated the unique and novel properties claimed for the compound, and that a person of ordinary skill in the art would reasonably ascribe to the claimed compounds the contributing cause for the differences between the end product when made from the prior art and when made from the claimed compound. We hold the District Court was correct both in his findings of fact and conclusions of law; we should make clear that our opinion with respect to this issue is predicated on the availability of both primary and secondary evidence, and on the sufficiency of this evidence to show the existence of a novel and unobvious property.
Affirmed.
. Deutsche Gold-und-Silber-Scheideanstalt Vormals Roessler v. Commissioner of Patents, 251 F.Supp. 624 (D.D.C.1966). Suit was instituted in that court by Appellee under 35 U.S.C. § 145 (1964) to compel Appellant to issue a patent following denial of the application by an Examiner and the Patent Office Board of Appeals.
. The Patent Office Solicitor conceded that the Commissioner’s approach was “revolutionary” at oral argument. The amicus takes a similar view:
It is the considered opinion of amicus that the foregoing propositions advanced by tile Commissioner are so far reaching in their implications and so sweeping in their scope that any decisions of this Court approving them would unquestionably be revolutionary in its import in the patent field.
Brief for Amicus Curiae, American Patent Law Association, p. 5.
. Patent Office Rule 132. See r/enerally Seidman & Horowitz, Patent Office Rules and Practice § 132.1 (rev.ed. 1962).
. Appellee withdrew one of the three process claims in the District Court. Thus, only two process claims have been allowed.
. The showing was made as to the sedative and antihistamine derivatives, Andantol and Dominal. When these compounds were derived from the claimed compounds they purported to have superior pharmacological properties than when derived from other compounds. Since no demonstration was made of the properties of the compounds themselves when used as intermediates, the Board held that the pharmacological properties of the final ■ product did not relate back to the compound used in its preparation, citing Application of Druey, 319 F.2d 237, 50 CCPA 1538 (1963). See discussion infra.
. The three statutory conditions of patentability are novelty and utility, as defined in 35 U.S.C. §§ 101-102. (1964), and non-obviousness, as set out in section 103. For an historical discussion of Graham v. John Deere Co.: New Standards for Patents, 1966 Sup.Ct. Rev. 293.
. Hotchkiss v. Greenwood, 52 U.S. (11 How.) 248, 13 L.Ed. 683 (1851), which gave birth to the “invention” standard eventually replaced by section 103’s requirement of “non-obviousness.”
. The Examiner’s decision seems quite clear that lie was considering the differences in the prior art in light of the level of ordinary skill in the art of pharmacology. Furthermore, the references relied upon demonstrate utility in pharmocological activities. We assume the correctness of that decision but we note that the determination of what is the “art” is not easy.
. A chemical analog is an organic compound having a closely related structure to another compound.
. Isomers are different compounds which have the same molecular formula but different molecular structures. Thus, while they contain the same number of the same kinds of atoms, the atoms are attached to one another in different ways.
. Twice in its opinion the court states that “none of the references broadly or specifically disclose” the claimed compound, 251 F.Supp. at 627, 630. In each instance the opinion immediately proceeds to a discussion of properties as if structural obviousness was present and conceded. A careful reading of these portions of the opinion, however, indi
. See Hays v. Brenner, 123 U.S.App.D.C. 96, 98, 357 F.2d 287, 289 (1966); California Research Corp. v. Ladd, 123 U.S. App.D.C. 60, 64, 356 F.2d 813, 817 (1966); Stieg v. Commissioner of Patents 122 U.S.App.D.C. 361, 353 F.2d 899 (1965); Esso Standard Oil Co. v. Sun Oil Co., 97 U.S.App.D.C. 154, 156-157, 229 F.2d 37, 39-40, cert, denied, 351 U.S. 973, 76 S.Ct. 1027, 100 L.Ed. 1491 (1956). Cf. Baenitz v. Ladd, 124 U.S.App.D.C. 237, 239-240, 363 F.2d 969, 971-972 (1966) (process claim). It is true that these cases refer to the determination by the Patent Office or the District Court of non-obviousness of the subject matter as a whole. However, we believe that these standards are equally applicable to segments of the overall determination such as structural obviousness. It is now clear that the Court of Customs and Patent Appeals would not apply a “clearly erroneous” rule because they are of the view that the determination of “obviousness” is a legal, not a factual conclusion. Application of Warner, 379 F.2d 1011, 1016 n. 6 (1967). We remain of our view, most recently implied in Higley v. Brenner, 128 U.S.App.D.C. 290, 387 F.2d 855 (1967), and National Distillers & Cliem. Corp. v. Brenner, 128 U.S.App. D.C. 386, 389 F.2d 927 (1967), that this is a factual conclusion based on a legal standard; thus the clearly erroneous rule applies.
. A homolog is a member of a series of compounds in which each member differs from the next member by a constant number of atoms. For example, the alkane family forms a homologous series, the constant difference between successive members being one carbon atom and two hydrogen atoms, e. g., CH4 (methane), C2H5 (ethane), etc. See notes 9-10 supra, for definitions of analogs and isomers.
. See E. I. DuPont de Nemours & Co. v. Ladd, 117 U.S.App.D.C. 246, 328 F.2d 547 (1964); Parker v. Marzall, 92 F. Supp. 736 (D.D.C.1950); Application of Papesch, 315 F.2d 381, 50 CCPA 1084 (1963).
. See, e. g., Application of Lohr, 317 F.2d 388, 50 CCPA 1274 (1963).
. For recent discussion see Application of McLamore, 379 F.2d 985, 989-990 (C.C.P.A.1967); Application of Wagner, 371 F.2d 877 (C.C.P.A.1967); Application of Lunsford, 357 F.2d 380 (C.C.P.A.1966).
. See Western, Is 35 U.S.C. § 103 Applicable to Chemical Compounds? 8 Idea 443 (1964); Note, 32 Geo.Wash. L.Rev. 429 (1963).
. The Commissioner's position, here paraphrases the Board of Patent Appeals in Papeseh:
Such proof of advantages is not seen to occupy a different relationship than proof of commercial success or of the “filling of a long-felt want” often considered as sufficient to establish patentability in cases where some doubt of unobviousness exists, but which have been consistently held as insufficient alone to override the holding of unpatentability in a clear case of obviousness.
Papesch, supra, 315 F.2d at 386 (emphasis by court). It was rejected by the Papeseh court. It may well be true that in the field of chemistry, the discovery of useful properties will be the factor primarily responsible for commercial success or a solution to a long felt need, but that alone does not make it a secondary factor.
. As was stated at a recent seminar on pharmaceutical invention, [t]ake away the concept of molecular modification and very few of our most outstanding drugs would be available today. Thus, the difference between morphine and codeine is a methyl group; between 11 desoxycorticosterone, which does nothing for humans, and cortisone, which does everything, is one oxygen atom.
Seminar, Pharmaceutical Invention, 47 J. Pat.Oi'V.Soc’y 648, 682 (1965).
. We are not unmindful that we are dealing in the area commonly referred to by the patent bar as the Hass-Henze area, so named for the three Hass eases, 141 F.2d 122, 127, 130, 31 CCPA 903, 908 (1944) and Application of Henze, 181 F.2d 196, 37 CCPA 1009 (1950). These cases antedate section 103 and establish a rule that proof of the existence of unobvious or unexpected beneficial properties in a new compound which would otherwise appear obvious, is indicative of patentability. Much has been written on the subject with little clarification. For a discussion of the doctrine, its limitations and the significance of homology see Application of Mills, 281 F.2d 218 (C.C.P.A.1960). For a general discussion see Guttag, The Hass-Henze Doctrine, 43 J.Pat. Off.Soc’y 808 (1961); Collins, The Forgotten Chemistry of the Hass-Henze Doctrine, 44 J.Pat.Off.Soc’y , 284 (1962); see also Western, supra note 17; Note, 32 Geo.WashL.Rev. 423 (1963).
. The Commissioner correctly recognizes the difficulty of patenting new but obvious chemical compounds on the basis of novel properties and new uses. This problem of overclaiming arises from the fact that the patent is given for the entire compound, although based on only one new property it discloses. Thus, the patent holder of compound A, with properties X and Y, is foreclosed from using newly patented, structurally obvious compound B, with obvious properties. X and Y, merely because compound B also possesses new and unobvious property Z. Whether or not the solution rests in strictly limiting patentability to the new use alone, or to the process by which it is made, however, is a matter for the Commissioner, the Congress, and courts with greater technical expertise to decide in the first instance. See Western, supra note 17, at 449-452.
. When the inherent existence of a certain beneficial utility in a claimed compound is itself unobvious, a requirement that an applicant must additionally show that his compound is unexpectedly more useful in comparison with prior art compounds would amount to a requirement to prove “advance in the art”, which is not a condition or patentability under American Patent Law. 35 U.S.C. §§ 101-103. 251 F.Supp. at 628 (emphasis added).
. The following statements are indicative of those relied upon by the Commissioner:
In administering the patent law, the court first looks into the art, to find what the real merit of the alleged discovery or invention is, and whether it has advanced the art substantially.
Eibel Process Co. v. Minnesota & Ontario Paper Co., 261 U.S. 45, 63, 43 S.Ct. 322, 328, 67 L.Ed. 523 (1923).
[P]atentable invention must be measured by the advance which it teaches over the prior art.
Helene Curtis Indus., Inc. v. Sales Affiliates, Inc., 233 F.2d 148, 154 (2d Cir. 1956).
We are bound first to look into the prior art to ascertain what may be the real merit of the invention and to decide whether or not it has substantially advanced the art.
L-O-F Glass Fibers Co. v. Watson, 97 U.S.App.D.C. 69, 76, 228 F.2d 40, 47 (1955).
The statute permits the Patent Office to grant a patent only where invention, novelty, and utility coexist. * * * Advance over the art is a fourth element implicit in that recital.
Application of Henze, 181 F.2d 196, 201, 37 GCPA 1009 (1950).
. After a lapse of 15 years, the Court again focuses its attention on the patentability of inventions under the standard of Art. I, § 8, cl. 8, of the Constitution and under the conditions prescribed by the laws of the United States. 383 U.S. at 3, 86 S.Ct. at 686 (emphasis added).
. Id. at 6, 86 S.Ct. 684.
. Id. at 5, 86 S.Ct. 684.
. E. g., id. at 14, 86 S.Ot. 684 at 692.
. We requested the Solicitor to file a supplemental memorandum on this point which he has done, but we do not find it compelling. For example, he relies upon Murray Co. of Texas, Inc. v. Continental Gin Co., 264 F.2d 65 (5th Cir. 1959), and Imperial Stone Cutters, Inc. v. Schwartz, 370 F.2d 425 (8th Cir. (1966), for support. The first case is distinguishable as a combination patent. And in the second case the Eighth Circuit found both obviousness and lack of utility, which seem to demonstrate that no advance in the art was possible. The memorandum failed to disclose any case holding that a claimed subject matter was not patentable, because it did not advance the art, even though it was new, useful and nonobvious.
. This is not to say, of course, that these may not be secondary factors for consideration as evidencing one of the three statutory conditions.
. The Court of Customs and Patent Appeals lias consistently held that the claimed subject matter need not be better than the prior art. B. g., Application of Ratti, 270 F.2d 810, 46 CCPA 976 (1959). And compare Hotchkiss v. Greenwood, 52 U.S. (11 How.) 248, 13 L.Ed. 683 (1851), the case establishing the invention condition wherein the Court rejected dissenting Justice Woodbury’s opinion that the test should be “cheaper and better,” id. at 267.
. Indeed, if we properly understand the Commissioner’s position on the Graham case, he is using the advancement standard in such a manner that design patents would be invalid as well as many other accepted patentable subjects, e. g., toys. See Note, 54 Geo.L.J. 1320, 1337-1339 (1906).
. The parties have each sought to place alternative arguments before us. Thus, the Appellee asserts that an advance was made in this case, an argument better addressed to the evidentiary issue, while the Commissioner argues that the advance must be “substantial.” We need not reach these arguments in view of our disposition of the issue. We should note, however, that the two cases relied upon by the Commissioner, American Infra-Red Radiant Co. v. Lambert Indus., Inc., 360 F.2d 977 (8th Cir. 1966), and Howe v. General Motors Corp., 252 F. Supp. 924 (N.D.Ill.1967) do not establish advancement as a separate and unique standard but rather address themselves to the question of non-obviousness, thus equating the two. The language in those opinions about substantial advances is properly addressed to non-obviousness.
. Anthelmintic activity is an activity which is directed against worms which are parasitic in animals and, in some cases, humans, e. (/., intestinal parasites such as ascaris worms.
. The toxicity tests were based on the largest dosage of the claimed compound and its prior art isomers which was required before fifty per cent of the host animals tested were destroyed. The importance of the toxicity ratio is clear. Thus, the utility of any drug is circumscribed if it causes severe illness or death.
. The prior art relied upon did not disclose any specific utility or property. The Rath patent for azaphenothiazine compounds provides the sole indication of therapeutic utility disclosed in the prior references. Rath’s compounds are said “to be distinguished by relatively low toxicity and valuable physiological effects based on their cajjacity for stabilizing the vegetative and central nervous system, * * 251 F.Supp. at 627 (quoting the Rath Application, No. 2,789,978, April 23, 1957). No other utility or property is disclosed in the other prior art references.
. The District Judge found that the government’s attempt to distinguish DuPont was erroneous in light of Application of Brown, 329 F.2d 1006, 51 CCPA 1254 (1964). We do not believe that the Broion opinion equates the two sections for all purposes, nor do we find Broion to be pertinent to the problem here.
. Application of Mills, 281 F.2d 218, 221-223 (C.C.P.A.1960); Application of Elpern, 326 F.2d 762, 51 CCPA 883 (1964); Application of Wagner, 371 F.2d 877, 883-884 (C.C.P.A.1967).
. We should point out that this is not a case where the prior art disclosed the same utility thus requiring the applicant to demonstrate by clear and convincing evidence that his claimed compound has substantially greater effectiveness. Application of McLamore, 379 F.2d 985, 987 (C.C.P.A.1967); Application of Risse, 378 F.2d 948, 958 (C.C.P.A.1967); Application of Wagner, 371 F.2d 877, 883 (C.C.P.A.1967) ; Application of Wiechert, 370 F.2d 927, 931-932 (C.C.P.A. 1967); Application of Rosselet, 347 F.2d 847, 850, 52 CCPA 1533 (1965); Application of Ruschig, 343 F.2d 965, 52 CC PA 1238 (1965); Application of Lohr, 317 F.2d 388, 392, 50 CCPA 1274 (1963). Certainly where the prior art references expressly show a utility in the same narrow pharmacological area, comparative tests of greater effectiveness are the sine Qua non of patentability. Nor is this a case where the property of the claimed compound was exactly opposite that of the prior art reference. Application of Petering, 301 F.2d 676, 49 CC PA 993 (1962); Application of Lambooy, 300 F.2d 950, 49 CCPA 985 (1962). Of. Application of Wagner, supra, 371 F. 2d at 883-884. In fact, there is absolutely no suggestion that it was obvious to a chemist that the prior art isomers of Appellee’s claimed compound would have the anthelmintic properties claimed in the specification.
. The court indicated that such evidence was admissible if the application was able to demonstrate why such tests were necessary or why no direct tests were possible. 174 F.2d at 135. This modification has been subsequently followed. See cases cited infra note 40.
. Ex parte Ullyot, 103 U.S.P.Q. 185 (P.O.Bd.App.1952); Ex parte Parker and Adams, 102 U.S.P.Q. 367 (P.O.Bd. App.1950).
. Application of Diamond, 360 F.2d 214 (O.O.P.A.1966); Application of Widmer, 353 F.2d 752 (O.C.P.A.1965); Application of Druey, 319 F.2d 237, 50 CCPA 1538 (1963); Application of Surrey, 319 F.2d 233, 50 CCPA 1336, cert, denied, 375 U.S. 930, 84 S.Ct. 332, 11 L.Ed.2d 264 (1963). The District Judge relied upon two best evidence cases from the District Court here, Union Carbide Corp. v. Brenner, 239 F.Supp. 923 (D.D.C.1964) ; Parker v. Marzall, 92 F.Supp. 736 (D. D.C.1950). We agree but hasten to point out that these cases fit within the framework of the best evidence rule and do not indicate this circuit’s disagreement with the rule.
Dissenting Opinion
(dissenting):
In Graham v. John Deere Co., the Supreme Court stated that the “inquiry which the Patent Office and the courts must make as to patentability must be beamed with greater intensity on the [non-obviousness] requirements of § 103 * * 383 U.S. 1, 19, 86 S.Ct. 684, 694 (1966). I respectfully submit that
There is no question that the claimed compound is structurally obvious. The majority concludes that such a compound can meet the requirements of § 103 if it has novel properties. I need not decide whether this conclusion is correct because I believe there was no adequate showing that the claimed compound in fact possessed novel properties.
The only method of proving that a compound has properties not possessed by the prior art is comparative testing. Here the majority concedes that the comparative testing was not comprehensive. Furthermore, the trial judge’s ability to evaluate the limited comparative evidence was undoubtedly undermined by his belief that:
When the prior art does not contain the slightest suggestion that the properties of a claimed compound would make it useful for a certain advantageous purpose, then the utility itself is unobvious, and it is unnecessary for an applicant to prove by comparative tests that his compound is more useful for the certain purpose than closely related prior art compounds.
Finally, the district judge only concluded that the claimed compound was “equal or superior as a vermicide” to the prior art compounds. This is not a clear cut finding of novel properties.
The majority refuses to require further comparative testing in this ease because the appellee “went on to offer further evidence of a secondary nature — the indirect utility of the claimed compound as an intermediate for the production of known drugs with greater effectiveness than when prepared under then-existing methodology.” There is some question as to whether such secondary evidence is admissible.
when utilized as a vermicide. Thus I think the court’s opinion today fails to heed the admonition of the Supreme Court in Graham v. John Deere Co.
. See e. g., Application of Druey, 319 F.2d 237, 50 COPA 1538 (1963) ; Application of Finley, 174 F.2d 130, 36 COPA 998 (1949).